Related Experiment Video
Updated: May 27, 2026
05:39
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy
Maki Shinzawa1, Ryohei Yamamoto, Yasuyuki Nagasawa
1Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Clinical and Experimental Nephrology
|November 11, 2011
Summary
Genetic factors like CD14 and ACE influence hypertension in IgA nephropathy patients. Identifying these genetic links, such as CD14 C-159T and ACE I/D, can help refine treatment strategies for chronic kidney disease.
Area of Science:
- Nephrology
- Genetics
- Cardiovascular Medicine
Background:
- Hypertension is a major risk factor for chronic kidney disease, influenced by genetic and environmental factors.
- Identifying genetic contributors to hypertension in chronic kidney disease patients may improve therapeutic strategies.
Purpose of the Study:
- To investigate the association between specific genetic polymorphisms and hypertension in patients with immunoglobulin A nephropathy (IgAN).
Main Methods:
- A multicenter cross-sectional study included 240 IgAN patients (aged 15-50 years, urinary protein ≥0.25 g/day).
- Hypertension was defined by blood pressure readings or antihypertensive use.
- Associations between hypertension and 28 polymorphisms were assessed using Chi-squared tests and multivariate logistic regression.
Main Results:
- The CD14 (-159CC) and ACE (DD) genotypes were significantly associated with hypertension after Bonferroni correction.
- Multivariate analysis confirmed CD14 -159CC (OR 3.58) and ACE DD (OR 4.41) as independent predictors of hypertension.
Conclusions:
- The CD14 C-159T and ACE I/D polymorphisms are significant contributors to hypertension development in patients with IgAN.
- These findings highlight potential genetic targets for managing hypertension in IgAN.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...